NASDAQ · LPCN
Lipocine Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LPCN: Nov 5, 2026
Lipocine Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.39. The reported EPS for the same quarter last year was $-0.59.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Dec 2026 | $-0.33 | $-0.33 | $-0.33 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · Fintel- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- Zacks · Oct 8, 9:57 AM EDTHere's Why You Should Add LPCN Stock to Your Portfolio NowLipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
- RTTNews · Oct 7, 9:50 AM EDTLipocine Jumps On TLANDO's Health Canada Approval For Testosterone Replacement Therapy(RTTNews) – Lipocine Inc. (LPCN), a speciality pharmaceutical company focused on developing oral therapeutics, announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules, through its licensing partner Verity Pharmaceuticals, for testosterone replacement
- BNK Invest · Oct 5, 1:45 PM EDTMonday 10/5 Insider Buying Report: LPCN, CSWCAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Lipocine, a filing with the SEC revealed that on Wednesday, Director John W. Hig
- Zacks · Sep 23, 11:00 AM EDTLipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · May 7, 3:15 PM EDTLipocine (LPCN) Reports Q1 Loss, Beats Revenue EstimatesLipocine (LPCN) delivered earnings and revenue surprises of -5.88% and +19.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 6, 9:30 AM EDTBioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue EstimatesBioCryst (BCRX) delivered earnings and revenue surprises of -150.00% and +0.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Apr 2, 9:42 AM EDTLipocine Stock Tanks 78% After Phase 3 Oral Brexanolone Trial Failed To Meet Primary Endpoint(RTTNews) – Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the primary endpoint. The trial evaluated LPCN 1154 or oral brexanolon
- RTTNews · Apr 2, 8:35 AM EDTLipocine: LPCN 1154 Fails To Meet Primary Endpoint; Plans To Evaluate All Available Options(RTTNews) – Lipocine (LPCN) announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 or oral brexanolone for the treatment of postpartum depression. In the trial, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D t
- Fintel · Mar 26, 11:24 PM EDTLipocine (LPCN) Price Target Increased by 19.54% to 13.26The average one-year price target for Lipocine (NasdaqCM:LPCN) has been revised to $13.26 / share. This is an increase of 19.54% from the prior estimate of $11.09 dated February 21, 2026. The price target is an average of many targets provided by analysts. The
- Zacks · Feb 27, 7:44 AM ESTLipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Feb 26, 6:00 PM ESTRelay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue EstimatesRelay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.51% and -52.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Lipocine Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.